Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call

On Tuesday, Lineage Cell Therapeutics (AMEX: LCTX ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more.

View the webcast at Summary Lineage Cell Therapeutics Inc reported a strong expansion of its Alloscope cell manufacturing platform, leading to the launch of the Cor1 corneal endothelial cell transplant program. The Opregen program shows promise as a potentially disease-modifying treatment for dry AMD, with expanded clinical sites and positive advancements reported by partners Roche and Genentech. The company is focusing on scalable manufacturing processes to ensure commercial viability before launching clinical trials, emphasizing the importance of process consistency in cell therapy. 4 million expected to support operations into Q2 2028.

Strategic collaborations with William Demant Invest and Roche/Genentech continue to progress, potentially providing substantial future milestone payments. Future plans include advancing the OPC1 spinal cord injury program, the Resonance auditory neuronal cell transplant for hearing loss, and new islet cell and corneal endothelial cell initiatives. Full Transcript OPERATOR Welcome to the Lineage Cell Therapeutics First Quarter 2026 Conference Call. At this time, all participants are in a listen-only mode.

An audio webcast of this call is available on the Investors section of the Lineage website at This call is subject to copyright and is the property of Lineage. Recordings, reproductions, or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage.

Ms. Hone, please go ahead. Ioana Hone, Head of Investor Relations Thank you. Good afternoon and thank you for joining us.

A press release reporting our first quarter 2026 financial results was issued earlier today, May 12, 2026, and can be found on the Investor section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties.

The Company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the Company's results or performance to differ, we refer you to the forward-looking statement sections in today's press release and in the company's SEC filings, including its most recent annual report on Form 10-K and in the Form 10-Q filed today. We caution you not to place undue reliance on any forward-looking statements, which speak only as of today and are qualified by the cautionary statements and risk factors described in our SEC filings.

With us today are Brian Culley, our Chief Executive Officer, and Jill Howe, our Chief Financial Officer. I will now hand the call over to Brian. Brian Culley, Chief Executive Officer Thank you. Good afternoon everyone.

Appreciate you taking the time to join us today. We have a lot of great things to cover. I'm going to try and keep it short so that we can have plenty of time for analyst questions. I do definitely want to highlight the successful expansion of Alloscope, our proprietary cell manufacturing platform.

Most notably because it led to the launch of Cor1, our new wholly owned corneal endothelial cell transplant program. We also successfully met our first internal milestone with our ILT1 manufacturing initiative and established a new scientific advisory board and attracted and recognized established cell therapy executive as its founding member. But before I share those and other updates, I'll begin with the status of our lead clinical program, Opregen. Data we reported several years ago from the Opregen Phase 1/2a clinical study included improved anatomy of the retina, halting or reversal of atrophic progression, and improved vision in patients with dry AMD.

These are compelling data because they're not known to occur naturally in human beings and since we made these initial reports, two additional and very important advancements have occurred in the field. The first of these is that three other companies have reported similar results with their own version of an RPE transplant, independently providing further evidence in support of the mechanism and its treatment effects. The second is that Roche Genentech's long-term analysis of our data show that vision gains persisted for at least three years following a single administration of cells among patients who received those cells to the target location.

Taken together, these data appear to us to be consistent with continued forward progress of the Opregen program. And while we await a decision on the future of the Opregen program, I'll note that while we've long believed that we may be seeing a potential functional cure for advanced dry AMD in the Opregen program, this month's presentation by our partners Roche and Genentech is the first time that they have used similar language to describe Opregen as a potentially disease-modifying treatment.

Obviously, even discussing disease modification and geographic atrophy is exceptionally promising because dry AMD is a common condition that has not been shown to self-resolve and only leads to worsening vision. So we find it notable that after adding only a single site in 2024, Genentech has now